Market capitalization | $9.73m |
Enterprise Value | $11.00m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 30.56 |
P/S ratio (TTM) P/S ratio | 27.03 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -56.85% |
Revenue (TTM) Revenue | $360.00k |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
2 Analysts have issued a Vaccinex, Inc. forecast:
2 Analysts have issued a Vaccinex, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.36 0.36 |
57%
57%
|
|
Gross Profit | 0.25 0.25 |
62%
62%
|
|
EBITDA | -22 -22 |
1%
1%
|
EBIT (Operating Income) EBIT | -22 -22 |
2%
2%
|
Net Profit | -18 -18 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vaccinex, Inc. is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington's disease. Its products pipeline includes SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.
Head office | United States |
CEO | Maurice Zauderer |
Employees | 40 |
Founded | 1997 |
Website | www.vaccinex.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.